P37231

PTMD Annotation Information

※ Protein Information

Tag	Content
UniProt Accession	PPARG_HUMAN; P37231;
Entrez ID	5468
GenBank Protein ID	NM_005037.5; NM_015869.4; NM_138711.3; NM_138712.3; XM_011533841.2;
GenBank Nucleotide ID	NP_005028.4; NP_056953.2; NP_619725.2; NP_619726.2; XP_011532143.1;
Protein Name	Peroxisome proliferator-activated receptor gamma (PPAR-gamma) (Nuclear receptor subfamily 1 group C member 3)
Gene Name	PPARG; NR1C3
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).;(Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein. Functional Description Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).;(Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein.
Sequence (Fasta)	MGETLGDSPI DPESDSFTDT LSANISQEMT MVDTEMPFWP TNFGISSVDL SVMEDHSHSF 60 DIKPFTTVDF SSISTPHYED IPFTRTDPVV ADYKYDLKLQ EYQSAIKVEP ASPPYYSEKT 120 QLYNKPHEEP SNSLMAIECR VCGDKASGFH YGVHACEGCK GFFRRTIRLK LIYDRCDLNC 180 RIHKKSRNKC QYCRFQKCLA VGMSHNAIRF GRMPQAEKEK LLAEISSDID QLNPESADLR 240 ALAKHLYDSY IKSFPLTKAK ARAILTGKTT DKSPFVIYDM NSLMMGEDKI KFKHITPLQE 300 QSKEVAIRIF QGCQFRSVEA VQEITEYAKS IPGFVNLDLN DQVTLLKYGV HEIIYTMLAS 360 LMNKDGVLIS EGQGFMTREF LKSLRKPFGD FMEPKFEFAV KFNALELDDS DLAIFIAVII 420 LSGDRPGLLN VKPIEDIQDN LLQALELQLK LNHPESSQLF AKLLQKMTDL RQIVTEHVQL 480 LQVIKKTETD MSLHPLLQEI YKDLY 506 Fasta Sequence >P37231\|PPARG; NR1C3\|Homo sapiens (Human) MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Tyrosine Phosphorylation	Colon cancer/carcinoma		U	Y102	26718225
1	[Reference]: EGFR/MDM2 signaling promotes NF-?B activation via PPAR? degradation.

※ Disease Cross-ref Annotation

Database	Annotation
Cancer Gene Census	follicular thyroid
CTD (Curated) (count: 43) (view all)	MESH:D058186 ; Acute Kidney Injury MESH:D055371 ; Acute Lung Injury MESH:D000230 ; Adenocarcinoma MESH:D000544 ; Alzheimer Disease MESH:D016736 ; Antiphospholipid Syndrome MESH:D050197 ; Atherosclerosis MESH:D001471 ; Barrett Esophagus MESH:D006528 ; Carcinoma, Hepatocellular MESH:C563733 ; Carotid Intimal Medial Thickness 1 MESH:D021081 ; Chronobiology Disorders MESH:D003110 ; Colonic Neoplasms MESH:D015179 ; Colorectal Neoplasms MESH:D003424 ; Crohn Disease MESH:D003920 ; Diabetes Mellitus MESH:D003921 ; Diabetes Mellitus, Experimental MESH:D003924 ; Diabetes Mellitus, Type 2 MESH:D003928 ; Diabetic Nephropathies MESH:D050171 ; Dyslipidemias MESH:D005921 ; Glomerulonephritis MESH:D006333 ; Heart Failure MESH:D006973 ; Hypertension MESH:D007249 ; Inflammation MESH:D007333 ; Insulin Resistance MESH:D007511 ; Ischemia MESH:D018921 ; Leukostasis MESH:D008064 ; Lipidoses MESH:D052496 ; Lipodystrophy, Familial Partial MESH:D008113 ; Liver Neoplasms MESH:D016399 ; Lymphoma, T-Cell MESH:D008545 ; Melanoma MESH:D008659 ; Metabolic Diseases MESH:D009410 ; Nerve Degeneration MESH:D009765 ; Obesity MESH:D010003 ; Osteoarthritis MESH:D010190 ; Pancreatic Neoplasms MESH:D047748 ; Pituitary ACTH Hypersecretion MESH:D016891 ; Polycystic Kidney, Autosomal Dominant MESH:D011565 ; Psoriasis MESH:D051437 ; Renal Insufficiency MESH:D015427 ; Reperfusion Injury MESH:D013274 ; Stomach Neoplasms MESH:C572845 ; Thyroid cancer, follicular MESH:D013964 ; Thyroid Neoplasms
GWASdb (count: 41) (view all)	rs17036160; Type 2 diabetes; type 2 diabetes mellitus rs17036170; Drug-induced liver injury; drug-induced hepatitis rs2972164; Coronary artery calcification; coronary artery disease rs11709077; Multiple complex diseases; Null rs11709077; Alzheimer's disease; Alzheimer's disease rs11709077; Type 2 diabetes (females); type 2 diabetes mellitus rs11709077; Type 2 diabetes (males); type 2 diabetes mellitus rs4684846; Coronary artery calcification; coronary artery disease rs12631819; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs11128596; Coronary artery calcification; coronary artery disease rs12485478; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs12496505; Coronary artery calcification; coronary artery disease rs13433696; Coronary artery calcification; coronary artery disease rs7646510; LDL cholesterol; atherosclerosis\|coronary artery disease rs3892175; Alzheimer's disease; Alzheimer's disease rs12496005; Coronary artery calcification; coronary artery disease rs12490265; Urinary metabolites; kidney disease rs17036321; LDL cholesterol; atherosclerosis\|coronary artery disease rs11128603; Plasminogen activator inhibitor type 1 levels (PAI-1); type 2 diabetes mellitus\|coronary artery disease rs17036328; Multiple complex diseases; Null rs17036328; Fasting insulin-related traits; type 2 diabetes mellitus rs7649970; Type 2 diabetes; type 2 diabetes mellitus rs1801282; Type 2 diabetes; type 2 diabetes mellitus rs1801282; Alzheimer's disease; Alzheimer's disease rs1801282; Coronary heart disease; coronary artery disease rs1801282; Fasting insulin-related traits (interaction with BMI); type 2 diabetes mellitus rs1801282; Fasting insulin-related traits; type 2 diabetes mellitus rs1801282; Plasminogen activator inhibitor type 1 levels (PAI-1); type 2 diabetes mellitus\|coronary artery disease rs1899951; Type 2 diabetes; type 2 diabetes mellitus rs2938397; Lipoprotein-associated phospholipase A2 activity change in response to statin therapy; coronary artery disease\|atherosclerosis rs73025249; Menopause (age at onset); obesity\|type 2 diabetes mellitus\|cardiovascular system disease\|osteoporosis\|breast cancer\|Alzheimer's disease rs13306745; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs4135268; Memory performance; cognitive disorder rs4135275; Alcohol dependence; alcohol dependence rs73027210; Menopause (age at onset); obesity\|type 2 diabetes mellitus\|cardiovascular system disease\|osteoporosis\|breast cancer\|Alzheimer's disease rs114451007; Menopause (age at onset); obesity\|type 2 diabetes mellitus\|cardiovascular system disease\|osteoporosis\|breast cancer\|Alzheimer's disease rs17036700; Multiple complex diseases; Null rs1797912; Type 2 diabetes; type 2 diabetes mellitus rs4135361; LDL cholesterol; atherosclerosis\|coronary artery disease rs7626560; Urinary metabolites; kidney disease rs7650895; Urinary metabolites; kidney disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 6)	102 YDLKLQEYQSAIKVE dbPAF 112 AIKVEPASPPYYSEK dbPAF 269 RAILTGKTTDKSPFV dbPAF 273 TGKTTDKSPFVIYDM dbPAF 78 SSISTPHYEDIPFTR dbPAF 95 PVVADYKYDLKLQEY dbPAF
Ubiquitination (count: 3)	107 QEYQSAIKVEPASPP PLMD 220 MPQAEKEKLLAEISS PLMD 94 DPVVADYKYDLKLQE PLMD
Sumoylation (count: 4)	107 QEYQSAIKVEPASPP PLMD 364 MLASLMNKDGVLISE PLMD 395 FGDFMEPKFEFAVKF PLMD 63 HSHSFDIKPFTTVDF PLMD

※ Protein-Protein Interaction

Network

Interaction

A

B

Source

O75376	P37231	HPRD
P16949	P37231	IntAct
P28482	P37231	HPRD
P37231	P45983	HPRD
P37231	Q12778	HPRD
P37231	Q15466	HPRD
P37231	Q3V6T2	IntAct
P37231	Q92905	HPRD
P37231	Q9UBL3	DIP